musculoskeletal and connective tissue disorders
Relapsing Polychondritis
Prognosis for Relapsing Polychondritis
Mortality rates have decreased with newer therapies. Survival is now 94% after 8 years, with death typically resulting from collapse of laryngeal and tracheal structures or from cardiovascular complications such as large-vessel aneurysm, cardiac valvular insufficiency, or systemic vasculitis. Patients with VEXAS syndrome may develop hematologic neoplasms such as myelodysplastic syndrome and multiple myeloma. 